JLF025 / Jecho Biopharma - LARVOL DELTA

Development of JLF025, an anti-mesothelin T cell engager optimized for efficacy and safety (AACR 2025) - "In addition, combination of MSLN-490 with Atezolizumab or a chemotherapy drug paclitaxel produced a synergistic effect on tumor inhibition and more T cells were found infiltrated into tumors in the combo groups. In hMSLN and hCD3 double knock-in mouse, JLF025 demonstrated acceptable safety profiles. Thus, combination of JLF025 with immune checkpoint inhibitors and chemotherapy drugs represents a promising cancer treatment strategy and could be considered for future clinical trials."

Clinical • IO biomarker • Biliary Cancer • Breast Cancer • Lung Cancer • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • MSLN